H1 Miss on Rate Delays, FY27 25% Growth On Track

H1 revenue down 1.9% YoY to ₹667 Cr; recovery contingent on 60% H2 delivery (historical pattern)

Management explicitly stated ~₹100 Cr monthly business lost due to negotiation delay; recovery now underway with central government orders placed

OptraSCAN currently loss-making (₹15 Cr EBITDA loss H1); FDA approval achieved but real uptake deferred to FY28. Not yet accretive.

All three in late-stage validation; timeline to validation 3–4 months; market entry FY28. Execution risk remains on regulatory and commercial ramp.

Historical pattern consistent; current quarter reflects this seasonality plus one-time rate contract delay. Thesis supported by commentary on tender timing.

Rate contract renegotiation caused one-month delay, ~₹100 Cr monthly impact; recovery now underway with central government orders placed

FDA approval achieved but real uptake deferred to FY28 vs earlier H2 FY27 hopes; currently loss-making (₹15 Cr EBITDA loss H1)

Truenant vet, Truecycle, Truepoc all in late-stage validation; 3–4 months to completion, FY28 market entry firmed

Rate contract renegotiation caused one-month delay (~₹100 Cr monthly business). Central government tender now finalized; orders flowing. H2 recovery on track.

Hepatitis B & C assays approved in national algorithm; already in national program. Hepatitis devices on same Truenant machines.

Same platforms as human diagnostics. Vet is simpler market to reach; clinics lack testing facilities. Already have team in place, leveraging existing Truenant distribution.

All in parallel. Truenant continues growing both TB and non-TB. Vet will scale. Exports ramping. New platforms add breadth.

2–3 months to supply post-order. Payment 30–45 days post-delivery. Total cycle 60–75 days. Advantage: unique Truenant solution, established with ~10k machines in primary centers.

No separate market sizing available. Market is unorganized. We're creating a market. Truenant will be first point-of-care for vet clinics.

₹72 Cr automation already committed. With that, capacity can triple. No further major capex needed for our growth trajectory.

FDA approval 2.5 months ago. Clinical studies running in US labs. Real uptake expected next fiscal. Export activity rising in H2; process underway with CDSCO and other regulators.

Implies ~₹1,000+ Cr annual target; H1 ₹667 Cr, needs H2 to be 60% of annual (historical pattern). Government orders now placed.

H1 at 23% includes ₹15 Cr OptraSCAN loss. Normalized margin ~24%; OptraSCAN loss expected to halve or exit by year-end.

Equipment orders already placed; automation improves throughput for 25%+ growth trajectory without facility constraints.

40% H1, 60% H2 revenue split due to government tender cycles. Rate contract renegotiation caused one-month delay and ~₹100 Cr monthly impact. Central government orders now flowing, but contingent on procurement timelines.

OptraSCAN acquisition (FDA approved 2.5 months ago) incurring ₹15 Cr EBITDA loss in H1. Real revenue uptake deferred to FY28. Interest costs on term loan impacting PAT near-term.

3 new platforms (Truenant vet, Truecycle, Truepoc) in late-stage validation; 3–4 months to completion. FY28 market entry timelines ambitious. Execution risk on syndromic testing breadth and vet diagnostics adoption.

Vet market new and unorganized; no separate market sizing available. Molbio creating market vs displacing. Initial focus on companion animals (dogs, cats) before livestock. Adoption timeline and scale uncertain.

Export growth requires CDSCO manufacturing license (4–5 months away) + country-specific regulatory approvals. Delays could push export acceleration beyond FY27. Currently ₹120 Cr H1 (unproven scaling).